Technical Analysis for ONTX - Onconova Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 0.3 -16.90% -0.06
ONTX closed down 16.9 percent on Thursday, November 14, 2019, on 1.36 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ONTX trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
New Downtrend Bearish 0.00%
Expansion Breakdown Bearish Swing Setup 0.00%
Reversal New Lows Setup Bearish Swing Setup 0.00%
New 52 Week Low Weakness 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%

Older signals for ONTX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. Its products include Rigosertib intravenous (IV) that is in Phase III trials for higher risk myelodysplastic syndromes (MDS); Rigosertib Oral, which is Phase II clinical trials for patients with transfusion-dependent lower risk MDS and in patients with head and neck cancers; and Rigosertib IV, a combination therapy with gemcitabine in a Phase III clinical trials for the treatment of patients with metastatic pancreatic cancer. The company's products also comprise ON 013105 that is in Phase I clinical trials to treat various lymphomas and leukemias; and Recilisib, a molecule with radiation protection properties has completed four Phase I clinical trials. In addition, its preclinical products consist of ON 1231320, an inhibitor of polo-like kinase 2; ON 123300, an inhibitor of the cell cycle and cancer cell metabolism; ON 108600, an inhibitor of cyclin-dependent kinase 9 and casein kinase 2; ON 044580, a dual inhibitor of janus kinase 2 and Bcr-Abl kinase; ON 24 series of compounds that are oral anti-tubulin agents; and ON 146 series, which are selective inhibitors of PI3K alpha/delta isoforms. The company was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Biopharmaceutical Cancer Chemical Compounds Organic Compounds Radiation Myelodysplastic Syndrome Pyridines Tyrosine Kinase Inhibitors Bemcentinib Protein Kinase Inhibitors Lymphomas Head And Neck Cancers Kinase Leukemias Metastatic Pancreatic Cancer Heterocyclic Compounds Piperazines
Is ONTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.83
52 Week Low 0.2975
Average Volume 509,699
200-Day Moving Average 2.7243
50-Day Moving Average 1.0713
20-Day Moving Average 0.5995
10-Day Moving Average 0.4471
Average True Range 0.0988
ADX 25.87
+DI 13.6364
-DI 34.8509
Chandelier Exit (Long, 3 ATRs ) 0.9136
Chandelier Exit (Short, 3 ATRs ) 0.5939
Upper Bollinger Band 1.0096
Lower Bollinger Band 0.1894
Percent B (%b) 0.13
BandWidth 136.814012
MACD Line -0.1939
MACD Signal Line -0.2
MACD Histogram 0.0061
Fundamentals Value
Market Cap 2.95 Million
Num Shares 9.85 Million
EPS -2.57
Price-to-Earnings (P/E) Ratio -0.12
Price-to-Sales 9.36
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.42
Resistance 3 (R3) 0.43 0.41 0.40
Resistance 2 (R2) 0.41 0.38 0.40 0.39
Resistance 1 (R1) 0.35 0.36 0.34 0.34 0.39
Pivot Point 0.33 0.33 0.32 0.32 0.33
Support 1 (S1) 0.27 0.29 0.26 0.26 0.21
Support 2 (S2) 0.24 0.28 0.24 0.21
Support 3 (S3) 0.19 0.24 0.20
Support 4 (S4) 0.18